t e c h n i c a l r e p o r t s Molecular-genetic imaging is advancing from a valuable preclinical tool to a guide for patient management. The strategy involves pairing an imaging reporter gene with a complementary imaging agent in a system that can be used to measure gene expression or protein interaction or track genetagged cells in vivo. Tissue-specific promoters can be used to delineate gene expression in certain tissues, particularly when coupled with an appropriate amplification mechanism. Here we show that the progression elevated gene-3 (PEG-3) promoter, derived from a rodent gene mediating tumor progression and metastatic phenotypes, can be used to drive imaging reporters selectively to enable detection of micrometastatic disease in mouse models of human melanoma and breast cancer using bioluminescence and radionuclide-based molecular imaging techniques. Because of its strong promoter activity, tumor specificity and capacity for clinical translation, PEG-3 promoter-driven gene expression may represent a practical, new system for facilitating cancer imaging and therapy.
Targeted imaging of cancer remains a major but elusive goal. Such imaging could provide early diagnosis, aid in treatment planning and benefit therapeutic monitoring. By leveraging the expanding list of specific molecular characteristics of tumors and their microenvironment, molecular imaging has the potential to generate tumor-specific reagents. But many efforts at tumor-specific imaging are fraught by nonspecific localization of the putative targeted agents, eliciting unacceptably high background noise. Although investigators use many tumor-specific imaging strategies-largely in the service of maintaining high target-to-background ratios-they fall into two general categories, namely direct and indirect methods 1 . Direct methods employ an agent that reports directly on a specific parameter, such as a receptor, transporter or enzyme concentration, usually by binding directly to the target protein. Indirect methods use a reporter transgene strategy, in analogy to the use of EGFP in vitro, to provide a readout on cellular processes occurring in vivo by use of an external imaging device. Molecular-genetic imaging uses an indirect technique that has enabled the visualization and quantification of the activity of a variety of gene promoters, transcription factors and key enzymes involved in disease processes and therapeutics in vivo, including Gli 2 , E2F1 (ref. 3 ), telomerase 4, 5 and the herpes simplex virus 1 thymidine kinase (HSV1-TK) that has proved useful in human gene therapy trials 6, 7 .
A minimal promoter region of the gene encoding the rodent protein PEG-3 (Ppp1r15a; hereafter called the PEG-3 promoter) was identified by us for its association with malignant transformation and tumor progression by subtraction hybridization 8 . PEG-3 promoter drives downstream gene expression in a tumor-specific manner and has been tested in cancer cell lines of various tissues such as brain, prostate, breast and pancreas [9] [10] [11] , as well as in metastatic melanoma 12 . The transcription factors activator protein-1 and polyoma enhancer activator-3 are known to mediate the cancer-specific activity of PEG-3 promoter 8, 9, 13 . Previous studies have demonstrated the utility of PEG-3 promoter for cancer gene therapy through intratumoral delivery [9] [10] [11] [12] 14 . Here we describe a new method for imaging a variety of metastatic cancers through systemic delivery of PEG-3 promoter. We hypothesize that the systemic delivery of PEG-3 promoter-driven imaging constructs will enable tumor-specific expression of reporter genes, not only within primary tumor, but also in associated metastases in a manner broadly applicable to tumors of different tissue origin or subtype.
RESULTS

Cancer specificity of PEG-3 promoter by bioluminescence imaging
To test the specificity of the PEG-3 promoter for tumor imaging in vivo, we used two reporters, firefly luciferase (Luc) and HSV1-TK. Luc is often used with bioluminescence imaging to establish proof of principle for imaging specific gene expression or gene-tagged cells in preclinical models, whereas HSV1-TK, also often used preclinically, has been translated to clinical studies. Accordingly, we generated two plasmid constructs, pPEG-Luc and pPEG-HSV1tk ( Supplementary  Fig. 1a,b) . We chose to image the experimental metastasis models of two different tissues: human melanoma and breast cancer. As a gene delivery vehicle we used in vivo-jetPEI, which is based on linear polyethylenimine (l-PEI), one of the most widely used cationic polymers for gene delivery. We chose this inert (nonviral) vehicle rather than a Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression t e c h n i c a l r e p o r t s viral delivery system to avoid biased systemic delivery, as can be seen with viral vectors, which have a tendency to localize to liver upon intravenous (i.v.) administration 15, 16 .
After confirmation of the presence of metastatic nodules in the lung by computed tomography (CT) at 4-6 weeks after i.v. administration of the human malignant melanoma cell line MeWo or the human metastatic breast cancer cell line MDA-MB-231, mice received an i.v. dose of pPEG-Luc-PEI polyplex ( Fig. 1 and Supplementary Fig. 1a ). Twenty-four and 48 h after plasmid DNA delivery, we assessed PEG-3 promoter-driven gene expression by bioluminescence imaging. We applied the same plasmid DNA delivery and imaging protocols to a group of healthy mice as a negative control. Expression of Luc driven by PEG-3 promoter was observed only in the melanoma metastasis model and not in control mice (Fig. 1a,b) . Control mice demonstrated nearly background levels of bioluminescence imaging output at the 24 h time point that disappeared by the 48 h imaging session ( Supplementary Fig. 2a ). Quantification of the bioluminescence imaging signal intensity from the thoracic cavity, which represents Luc expression mainly in lung, shows significantly higher PEG-3 promoter activity in the melanoma group compared to controls at both time points after pPEG-Luc administration (Fig. 1c) , and more so at 48 h. We observed similar results in the model of breast cancer metastasis ( Fig. 1f-h) . Pseudocolor images of another representative mouse from the same control group shown in Figure 1a were readjusted for the breast cancer model such that the control and breast cancer groups are scaled to the same threshold values ( Fig. 1f) . As with the melanoma model, the quantified bioluminescence intensity from the thoracic cavity showed higher PEG-3 promoter activity in the breast cancer group compared to controls, and more markedly so 48 h after pPEG-Luc delivery ( Fig. 1h) . It took longer for the breast cancer group harboring MDA-MB-231 metastases than for the melanoma group with MeWo metastases to provide a significant increase in bioluminescence imaging signal over background (P = 0.0066; Fig. 1h ), probably resulting from the lower efficiency of gene delivery in the breast cancer model, as discussed below. Bioluminescence imaging images of all of the mice in each group (melanoma and breast cancer, as well as controls) at the same pseudocolor threshold values can be found in Supplementary Figures 2  and 3 , respectively.
On average, we observed an approximately three-fold higher level of Luc protein expression from the melanoma group compared to the breast cancer group at 48 h ( Fig. 1c,h) . CT scans and gross anatomical views revealed very different patterns of metastatic nodule formation in the lung of those two models ( Fig. 1e,i and Supplementary Fig. 4 ). Whereas MeWo cells formed small nodules uniformly scattered throughout the lungs ( Fig. 1e) , MDA-MB-231 cells tended to form isolated large nodules ( Fig. 1i) . Histological analysis showed that metastases derived from MeWo cells in the melanoma model were better vascularized ( Supplementary Fig. 4a ), whereas we observed necrotic centers in the nodules formed in the lungs of mice harboring breast cancer metastases derived from MDA-MB-231 cells (Supplementary Fig. 4b ). In addition to decreasing the efficiency of gene delivery, the poor vascularization and consequent central necrosis of the breast cancer tumors may limit access of d-luciferin and oxygen to the tumor, which are necessary concomitants for productive bioluminescence imaging signal.
To exclude the possibility that the tumor-specific expression of Luc detected by bioluminescence imaging might have resulted from the difference in transfection efficiency between normal and malignant mouse lung tissues, we quantified the amount of plasmid DNA delivered to the lung of each mouse. We performed quantitative real-time PCR with a primer set designed to amplify a region of the Luc-encoding gene in the pPEG-Luc plasmid. We used total DNA extracted from the lung tissues as a template. The difference in transfection efficiency between the control group and the melanoma group was not significant (Supplementary Fig. 5 ). In contrast, the breast cancer group had significantly lower transfection efficiency compared to the control (P = 0.0345) ( Supplementary Fig. 5 ). That result confirmed that the tumor-specific expression of Luc observed in these models was due to the tumor-selective activity of PEG-3 promoter rather than differential transfection efficiency between normal and malignant lungs. Poor vascularization and segregated large nodules probably contributed to lower transfection efficiency observed in the lung of the breast cancer mouse model (Supplementary Fig. 4 ). We also imaged constitutive cytomegalovirus (CMV) promoter activity in the lungs of the healthy control and melanoma groups as an additional check on the tumor specificity of PEG-3 promoter imaging ( Supplementary Fig. 6 ). Bioluminescence imaging showed no significant difference in the CMV promoter-driven Luc protein expression between the control and melanoma groups at any time up to 45 h after the systemic delivery of pCMV-Tri-PEI polyplex ( Supplementary  Fig. 6 ). This result indicates further that the specificity of PEG-3 promoter imaging results from tumor-specific promoter activity and not from tumor microenvironmental effects, such as increased tumor vascularity or enhanced tumor vascular permeability causing greater plasmid delivery or nonspecific effects on transgene expression.
Bioluminescence imaging with systemically administered pPEG-Luc also enabled imaging of small metastatic deposits, that is, micrometastases, outside of the lung parenchyma in both the melanoma and breast cancer models ( Figs. 2 and 3) . To confirm that Luc selectively expressed in metastatic sites was the source of bioluminescent signals, we collected regions producing bioluminescence imaging signal above background and performed correlative histological analysis ( Figs. 2 and 3) . Specifically, histological analysis on the tissue sections from a representative melanoma model, Mel-2 ( Fig. 2a) , confirmed that Luc expression was associated with the metastatic sites formed in the lung, adrenal glands, the chest cavity adjacent to the sternum and abdominal inguinal adipose tissues adjoining the bladder ( Fig. 2b-e, respectively) . Similarly, correlation between metastatic sites and PEG-3 promoter activity was observed in a representative breast cancer model, BCa-3 ( Fig. 3a) , inside the lung, the peripancreatic area, the thoracic wall adjacent to the sternum, a lymph node located in the adipose connective tissues surrounding the bladder and along the rib cage ( Fig. 3b-f, respectively) .
Radionuclide imaging of cancer via PEG-3 promoter
Although both malignant lung lesions and extrathoracic micrometastases could be detected with bioluminescence imaging, this technique is limited to preclinical studies as a result of several factors, including the need to administer luciferase substrate, the insufficient depth of penetration of bioluminescence imaging light output and the difficulty in generating quantitative, tomographic bioluminescence imaging-based images. Accordingly, we generated a more clinically relevant PEG-3 promoter-driven gene expression imaging system, pPEG-HSV1tk (Supplementary Fig. 1b) , which can be detected by radionuclide-based techniques, namely single-photon emission computed tomography (SPECT) or positron emission tomography (PET), upon administration of a suitably radiolabeled nucleoside analog.
We used the melanoma experimental metastasis model to show tumor-targeted imaging with SPECT-CT. Approximately 7 weeks after receiving MeWo cells as described above, the melanoma group and corresponding controls received pPEG-HSV1tk-PEI polyplex by i.v. injection. Forty-six hours after plasmid DNA delivery, we injected the mice with 2′-fluoro-2′-deoxy-β-d-5-[ 125 I]iodouracilarabinofuranoside ([ 125 I]FIAU) and imaged them at 24 and 48 h after they received the radiotracer (Fig. 4a,b and Supplementary Videos 1  and 2) . Quantification of radioactivity showed a 31-fold higher accumulation of [ 125 I]FIAU in the lungs of the melanoma model mice compared to controls, indicating the tumor-specific expression of HSV1-TK under the control of PEG-3 promoter ( Fig. 4c) . We further confirmed tumor presence in presumptive extrathoracic metastatic sites through gross histological analysis after the 48-h imaging session ( Fig. 5) . On the whole body SPECT-CT images ( Fig. 5a and Supplementary Video 1) we found multiple metastatic lesions in the dorsal neck of the Mel-2 mouse that corresponded to the intact histological specimen (Fig. 5b) . Metastatic sites, such as one to the left of the spinal cord ( Fig. 5c,d) , another immediately above the diaphragm (Fig. 5e,f) and another in the left inguinal lymph node (Fig. 5g,h) , similarly correlated with the whole-body SPECT-CT images in Mel-3. To evaluate the accuracy of detection and translational potential of PEG-3 promoter-mediated imaging, we compared the ability of the PEG-3 promoter system to detect lesions to that of [ 18 F]fluorodeoxyglucose (FDG), the clinical standard, in both melanoma and breast cancer models. We imaged the same mice with each method (Fig. 5i,j and Supplementary Fig. 7 ) and in most instances there was good correlation between the metastatic nodules detected by these two radionuclide-based techniques. However, the PEG-3 promoter-based system was better able to detect nodules adjacent to the heart and brown fat tissues, areas known to sequester FDG and cause high regional background signal 17, 18 . That finding is particularly noteworthy in light of the fact that SPECT is inherently at least one order of magnitude less sensitive than PET, and accumulation of [ 125 I]FIAU is limited to the tumor cells transfected with pPEG-HSV1tk-PEI that express the HSV1TK reporter, whereas FDG is taken up essentially by all viable malignant cells (Supplementary Fig. 7a ).
DISCUSSION
Our goal was to develop a systemically deliverable construct that would enable molecular-genetic imaging of cancer. The necessary elements for such a construct include a sufficiently strong promoter with cancer specificity, potential for clinical translation and capacity to be linked to gene therapy. Promoters derived from the human telomerase reverse transcriptase 4 , survivin 19 and carcinoembryonic antigen 20 promoters and enhancer elements have been used in molecular-genetic imaging to provide tumor-specific reporter expression. However, because those studies employed adenoviral vectors, delivery was limited to local administration, or systemic administration resulted in expression only within the liver. By contrast, here we could delineate metastases with PEG-3 promoter after systemic delivery with a nonviral vector. Often, promoter activity must be amplified to drive the downstream gene for purposes of imaging or therapy. One such strategy for doing so involves the two-step transcriptional amplification system 21, 22 using the GAL4-VP16 fusion protein and GAL4 response elements 19, 20, [23] [24] [25] . However, PEG-3 promoter did not require amplification to achieve high-sensitivity imaging. SPECT-CT imaging showed a metastatic to normal lung signal ratio of 31 out to 4 d after administration of pPEG-HSV1tk. PEG-3 promoter activity is comparable to the constitutively active SV40 promoter (data not shown). In keeping with previously reported in vitro results 9 , we show here that PEG-3 promoter proved to be tumor specific in vivo by both imaging modalities and in both tumor models tested, with the potential for further generalization to other modalities and tumors. We further chose pPEG-HSV1tk because of its capacity to be translated clinically. Clinical molecular-genetic imaging and gene therapy have been accomplished using HSV1tk and radiolabeled nucleoside analogs 7,26 and ganciclovir 6,27-29 , respectively. By using the l-PEI polyplex delivery vehicle we avoid the attendant problems of viral vectors in gene delivery, including immune reactions 30 and oncogenesis. Using plasmid DNA vectors the integration rate of the extrachromosomal gene into the host genome in vivo was negligible [31] [32] [33] [34] . We also estimated the potential of in vivo-jetPEI as a pPEG-HSV1tk delivery vehicle for detecting metastases in bone and brain, organs considered to be relatively difficult to access through systemic administration. Although lower than within lung, quantitative real time PCR demonstrated delivery of significant amounts of plasmid DNA to each of those tissues (Supplementary Fig. 8 ).
Since poorly vascularized necrotic areas within tumors contain less viable cells and are also difficult to reach through systemic delivery of imaging agents, molecular-genetic imaging techniques are expected to detect more accurately well-vascularized as opposed to predominantly necrotic lesions. Here we show how PEG-3 promoter can be used as an imaging agent for melanoma and breast cancer metastases in vivo and propose this promoter as potentially universal for this purpose. Such an agent might be used to detect tumors before their tissue of origin or subtype is identified, without concern for nonspecific expression in normal tissues. As with other imaging agents, PEG-3 promoter can be used not just for tumor detection, but also for preoperative planning, intraoperative management and therapeutic monitoring. The PEG-3 promoter imaging system can also be fashioned into a theranostic agent, through use of an internal ribosome entry site or other strategy enabling tandem gene expression. Promoters such as PSA (prostate-specific antigen) promoter 23, 24 for prostate cancer, mucin-1 promoter 25, 35 for breast cancer, and mesothelin promoter 36 for ovarian cancer have been used to delineate primary tumors and lymph node metastasis through molecular-genetic imaging. However, the activities of those promoters have not been tested more broadly, which would be needed to image a wide variety of tumors. Similarly, although human telomerase reverse transcriptase, survivin and carcinoembryonic antigen promoters were reported to be of a less tissue-and more cancer-specific nature, their activity relies on the transcription level of the marker genes. Rather, PEG-3 promoter is responsive directly to transcription factors unique to tumor cells. The Ppp1r15a gene is a truncated mutant form of the rat growth arrestand DNA damage-inducible gene, Gadd34, which occurs uniquely during tumorigenesis in the rat and may function as a dominantnegative form of GADD34 promoting the malignant phenotype 37 .
No homolog to PEG-3 promoter is found in the human genome, including the promoter and enhancer region of the human GADD homolog, which makes the use of PEG-3 promoter in human subjects likely to produce only minimal background signal 9, 37 .
In conclusion, these studies suggest that PEG-3 promoter may possess all of the necessary elements to provide a practical strategy for imaging and potentially image-guided therapy of a variety of cancers. Determination of the sensitivity and specificity of this system in vivo using radionuclide-based techniques in a variety of tissues, malignant and otherwise, is under way. Further optimization of the delivery vehicle and assessment of its effects on normal tissue are also being vigorously pursued.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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ONLINE METHODS
Plasmids. pPEG-Luc was constructed as described previously 9 . The firefly luciferase-encoding gene in pPEG-Luc was replaced by the HSV1-TK-encoding sequence from pORF-HSVtk plasmid (InvivoGen) to generate pPEG-HSV1tk. We prepared plasmid DNA with the EndoFree Plasmid Kit (Qiagen). Endotoxin level was ensured as <2.5 endotoxin units per mg plasmid DNA.
Systemic DNA delivery. Low-molecular-weight l-PEI-based cationic polymer, in vivo-jetPEI, (Polyplus transfection) provided the gene delivery vehicle. DNA polyplex was formed according to the manufacturer's instructions. We diluted 30 µg of plasmid DNA and 3.6 µl of 150 mM in vivo-jetPEI in endotoxin-free 5% (wt/vol) glucose separately and then mixed together to give an N:P ratio (that is, the ratio of the number of nitrogen residues of in vivo-jetPEI per the number of phosphate groups of DNA) of 6:1 in a total volume of 400 µl. We injected 400 µl into the lateral tail vein of a mouse as two 200-µl injections with a 5-min interval.
Generation of experimental metastasis models.
Mouse studies were undertaken in accordance with the rules and regulations of the Johns Hopkins Animal Care and Use Committee. Bioluminescence imaging studies used experimental metastasis models of human melanoma and breast cancer. We gave 5-to 6-week-old female NCR nu/nu mice (US National Cancer Institute-Frederick and Charles River Laboratories) whole-body irradiation (5 Gy) to ensure suppression of the residual immune system in nude mice. Within 24 h after irradiation, mice were randomly divided into three groups. One group was injected with 5 × 10 6 cells of the human malignant melanoma cell line MeWo (American Type Culture Collection) i.v. to generate a mouse model of melanoma metastasis. Another group of mice received i.v. injection of 2 × 10 6 cells of the human breast cancer cell line MDA-MB-231 for a model of breast cancer metastasis. The third group was maintained as a control. We confirmed the metastatic nodule formation in the lung by CT at 4-7 weeks after cell injection. For the SPECT-CT and PET-CT studies, we generated the melanoma and breast cancer models as described above except that whole-body irradiation was omitted. MeWo and MDA-MB-231 cell lines were maintained in MEM and RPMI-1640 media, respectively, supplemented with 10% (vol/vol) FBS and 1% (vol/vol) penicillin-streptomycin.
In vivo bioluminescence imaging. At 24 and 48 h after gene delivery, we imaged mice with the IVIS Spectrum (Caliper/Xenogen). For each imaging session, mice were injected intraperitoneally with d-luciferin (150 mg per kg body weight) under anesthesia using 1.5-2.5% isoflurane-oxygen mixture. Images were acquired between 5 and 35 min after injection of d-luciferin.
To compensate for the limitation of two-dimensional image acquisition, we imaged most mice in four positions: ventral, left, right and dorsal. Regions of interest of the same size and shape, covering the entire thoracic cavity, were applied to every image acquired from all four orientations to account for intragroup variations in metastatic site localization. Total flux (p s −1 ) in the regions of interest was measured. Image acquisition and bioluminescence imaging data analysis were done with Living Image software (Caliper Life Sciences).
SPECT-CT imaging and data analysis.
At 46 h after injection of pPEG-HSV1tk-PEI polyplex, mice were injected i.v. with 51.8 mBq (1.4 mCi) of [ 125 I]FIAU. Image data were acquired 24 and 48 h after radiotracer injection with the X-SPECT small-animal SPECT-CT system (Gamma Medica-Ideas) with the low-energy single pinhole collimator (1.0 mm aperture). Focused lung imaging was acquired with a radius of rotation of 3.35 cm and whole-body imaging with a radius of rotation of 6.75 cm. At 24 h after injection, mice were imaged in 64 projections and 30 s of acquisition per projection, and at 48 h after injection with 60 s per projection. SPECT images were co-registered with the corresponding 512-slice CT images. Tomographic image data sets were reconstructed with the two-dimensional ordered subsets-expectation maximum algorithm with two iterations and four subsets, and AMIDE 38 and Amira (Visage Imaging) softwares were used for analysis.
PET-CT imaging and data analysis.
At 1 h after 9.25 mBq (0.25 mCi) of i.v. administration of FDG, whole-body images were acquired with the eXplore Vista small animal PET scanner (GE Healthcare) using the 250-700 keV energy window. Acquisition time was 30 min (two bed positions; 15 min per bed position). Mice were fasted for 6-12 h before receiving FDG and were kept warm on the heating pad to minimize radiotracer accumulation in nontumor tissues. PET images were co-registered with the corresponding 512-slice CT images. Tomographic image datasets were reconstructed with the three-dimensional ordered subsets-expectation maximum algorithm with three iterations and twelve subsets and analyzed with AMIDE 38 software.
Immunohistochemistry. After the bioluminescence imaging data acquisition at 48 h after the pPEG-Luc-PEI polyplex delivery, each organ with expression of luciferase was collected and fixed in 10% neutral buffered formalin. Paraffin-embedded tissue slices and lung cryosections were stained with rabbit luciferase-specific polyclonal antibody (Fitzgerald Industries International, Inc.). Horseradish peroxidase-conjugated polyclonal goat rabbit-specific antibody was used as a secondary antibody. Horseradish peroxidase activity was detected with 3,3′-diaminobenzidine substrate-chromogen (EnVision + Kit, Dako).
Statistical analysis.
Error bars in graphical data represent means ± s.e.m. The two-tailed Student's t test was performed, with P < 0.05 considered statistically significant.
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